Targeted Sequencing Market size was valued at USD 2.5 Billion in 2022 and is projected to reach USD 5.7 Billion by 2030, growing at a CAGR of 13.8% from 2024 to 2030.
Targeted Sequencing Market Trends Explored: Insights from North America, Europe, and Asia-Pacific
The targeted sequencing market is witnessing significant growth across various regions, fueled by advancements in genetic research and personalized medicine. The demand for precise genomic data is reshaping healthcare, with North America, Europe, and Asia-Pacific leading the charge.
North America holds a substantial share of the global market, driven by the presence of major biotechnology companies and robust research funding. According to industry reports, the region is expected to account for over 45% of the market by 2025. Additionally, the U.S. healthcare infrastructure's focus on precision medicine is enhancing demand for targeted sequencing solutions.
In Europe, governments actively support genomic research through funding and regulatory frameworks. The European Union's Horizon 2020 initiative has fostered innovation in the life sciences sector, making Europe pivotal in the targeted sequencing landscape. As of 2023, the European market is projected to increase at a compound annual growth rate (CAGR) of 12%, bolstered by partnerships between academic institutions and industry players.
Asia-Pacific is emerging as a hotspot for targeted sequencing, attributed to rising investments in genomics. Countries like China and India are ramping up their research capabilities, with public health initiatives aiming to integrate genetic testing into standard medical practices. With a 14% CAGR forecast, this region's growth is transforming healthcare delivery.
North America: Expected to hold 45% market share by 2025.
Europe: CAGR of 12% driven by supportive regulations.
Asia-Pacific: Leading with 14% CAGR due to emerging markets.
As the targeted sequencing market expands, each region is adapting to unique challenges and opportunities, leading to diverse market dynamics that continuously evolve.
</>
Â
Download Full PDF Sample Copy of Automotive End-Point Authentication Market Report @ https://www.verifiedmarketreports.com/download-sample/?rid=265162&utm_source=Sites-google&utm_medium=283
Agilent Technologies
Azenta
BGI Group
Illumina
PerkinElmer
Thermo Fisher Scientific
Danaher
CD Genomics
Daicel Corporation
Takara Bio
Twist Bioscience
Psomagen
LGC Limited
Tecan Trading
PacBio
QIAGEN
Segmentation analysis involves dividing the market into distinct groups based on certain criteria, such as type and application. This helps in understanding the market dynamics, targeting specific customer groups, and devising tailored marketing strategies.
Â
Instruments
Services
Others
Â
Â
Academic and Research Institutions
Pharmaceutical and Biotech Companies
Diagnostic and Clinical Laboratories
Others
Â
North America (United States, North America and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Get a Discount On The Purchase Of This Report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=265162&utm_source=Sites-google&utm_medium=283
1. Introduction of the Targeted Sequencing Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Targeted Sequencing Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Targeted Sequencing Market , By Product
6. Targeted Sequencing Market , By Application
7. Targeted Sequencing Market , By Geography
North America
Europe
Asia Pacific
Rest of the World
8. Targeted Sequencing Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
For More Information or Query, visit @ https://www.verifiedmarketreports.com/product/targeted-sequencing-market/
Targeted sequencing is a technique used to selectively sequence specific regions of the genome.
The increasing adoption of personalized medicine and the rising prevalence of genetic disorders are driving the growth of the targeted sequencing market.
Targeted sequencing offers high accuracy, cost-effectiveness, and the ability to focus on specific genes or genomic regions of interest.
Targeted sequencing focuses on specific genomic regions, while whole genome sequencing covers the entire genome.
Targeted sequencing is used in cancer research, genetic disease diagnosis, and pharmacogenomics.
Challenges include data analysis complexities, variant interpretation, and standardization of methods.
North America and Europe are expected to dominate the targeted sequencing market due to favorable government initiatives and advanced healthcare infrastructure.
Key players include Illumina, Thermo Fisher Scientific, Agilent Technologies, and QIAGEN.
Next-generation sequencing (NGS) technology is enabling high-throughput targeted sequencing, thereby driving market growth.
Bioinformatics tools are crucial for data analysis, variant calling, and interpretation in targeted sequencing.
Targeted sequencing enables the identification of specific genetic variations that can inform personalized treatment decisions in precision medicine.
Targeted sequencing is being used to identify genetic markers associated with desirable traits in crops and livestock.
Advancements such as improved accuracy, reduced sequencing costs, and enhanced throughput are driving market growth.
Regulatory factors include approval processes for targeted sequencing assays and the protection of patient data privacy.
Future trends include the integration of artificial intelligence in data analysis, the expansion of target enrichment panels, and the emergence of portable sequencing devices.
Targeted sequencing enables the identification of rare genetic variants associated with rare diseases, aiding in diagnostics and treatment research.
Businesses should consider the competitive landscape, technological advancements, and collaborations with research institutions and healthcare providers.
Targeted sequencing facilitates the identification of genetic biomarkers that can be used in drug development for personalized medicine and targeted therapies.
Potential drawbacks include limited coverage of the genome, target bias, and the need for careful assay design and validation.
Targeted sequencing can lead to cost savings in healthcare by enabling more precise diagnostics, personalized treatments, and effective disease management.
</>
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.
We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Ceramic Material for MLCC Market Opportunities, Revenue with Expected CAGR of 6.3%
Instant Fat FiLled Milk Powders IFFMP Market Opportunities, Revenue with Expected CAGR of 5.4%
Ceramic Piezoelectric Transducers Market Opportunities, Revenue with Expected CAGR of 7.35%
Ceramic Sealed Contactors Market Opportunities, Revenue with Expected CAGR of 7.5%
Acetylated Distarch Adipate Market Opportunities, Revenue with Expected CAGR of 6.7%
Fresh Sausage Market Opportunities, Revenue with Expected CAGR of 5.2%